Selective group III metabotropic glutamate receptor antagonist. Displays an apparent KD of 51 μM for the L-AP4-sensitive presynaptic mGluR on primary afferent terminals in spinal cord compared to > 700 μM for the (1S,3S)-ACPD-sensitive presynaptic mGlu in the same system. Has no activity on postsynaptic mGlu receptors or on ionotropic glutamate receptors on neonatal rat motoneurons. Also available as part of the Group III mGlu Receptor Tocriset™.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 199.1. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||5.02 mL||25.11 mL||50.23 mL|
|5 mM||1 mL||5.02 mL||10.05 mL|
|10 mM||0.5 mL||2.51 mL||5.02 mL|
|50 mM||0.1 mL||0.5 mL||1 mL|
References are publications that support the products' biological activity.
Thomas et al (1996) α-Methyl derivatives of serine-O-phosphate as novel, selective competitive metabotropic glutamate receptor antagonists. Neuropharmacology 35 637 PMID: 8887973
If you know of a relevant reference for MSOP, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: MSOP, supplier, Specific, group, III, mGlur, antagonists, Group, Receptors, mGlu4, mGlu6, mGlu7, mGlu8, mGluR4, mGluR6, mGluR7, mGluR8, Glutamate, Metabotropic, Glutamate, (Metabotropic), Group, III, Receptors, Glutamate, (Metabotropic), Group, III, Receptors, Tocris Bioscience
5 Citations for MSOP
Citations are publications that use Tocris products. Selected citations for MSOP include:
Ster et al (2011) Enhancement of CA3 hippocampal network activity by activation of group II metabotropic glutamate receptors. J Neurosci 108 9993 PMID: 21628565
Spaziano et al (2015) Exposure to Allergen Causes Changes in NTS Neural Activities after Intratracheal Capsaicin Application, in Endocannabinoid Levels and in the Glia Morphology of NTS. Proc Natl Acad Sci U S A 2015 980983 PMID: 25866824
Derbenev et al (2006) Vanilloid-mediated heterosynaptic facilitation of inhibitory synaptic input to neurons of the rat dorsal motor nucleus of the vagus. J Physiol 26 9666 PMID: 16988037
Browning et al (2006) Vagal afferent control of opioidergic effects in rat brainstem circuits. Biomed Res Int 575 761 PMID: 16825311
Melyan et al (2004) Metabotropic regulation of intrinsic excitability by synaptic activation of kainate receptors. J Neurosci 24 4530 PMID: 15140923
Do you know of a great paper that uses MSOP from Tocris? If so please let us know.
Reviews for MSOP
There are currently no reviews for this product. Be the first to review MSOP and earn rewards!
Have you used MSOP?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.